790305-07-6

Upstream product

• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 61040-20-8 (S)-methyl 3-amino-2-((tert-butoxycarbonyl)amino)propanoate 
• 76387-70-7 (S)-3-amino-2-tert-butoxycarbonylaminopropionic acid 
• 635714-19-1 methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-{[(2-nitrophenyl)sulfonyl]amino}propanoate 
• 790305-06-5 2-tert-butoxycarbonylamino-3-[(2-nitro-benzenesulfonyl)-pent-4-enyl-amino]propionic acid methyl ester 

Downstream Products

• 1029004-72-5 (2S,4R)-methyl 4-(biphenyl-4-yl)-1-((S)-2-(tert-butoxycarbonylamino)-3-(2-nitro-N-(pent-4-enyl)phenylsulfonamido)propanoyl)-4-methoxypyrrolidine-2-carboxylate 

Relevant academic research and scientific papers

HCV PROTEASE INHIBITORS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula (I): are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.